



ORIGINAL ARTICLE

Wilms' tumour: A review of 15 years recent experience[☆]



Laura Illade^a, Carmen Hernandez-Marques^a, Maria Cormenzana^a,
Alvaro Lassaletta^{a,*}, Maitane Andión Catalán^a, David Ruano^a, Victoria Fioravanti^a,
Luis Madero López^b

^a Unidad de Onco-hematología Pediátrica, Hospital Niño Jesús, Madrid, Spain

^b Servicio Unidad de Oncohematología Pediátrica, Hospital Niño Jesús, Madrid, Spain

Received 28 January 2017; accepted 27 March 2017

Available online 3 February 2018

KEYWORDS

Renal tumour;
Wilms;
Nephroblastoma;
Children

Abstract

Introduction: Wilms' tumour is the most frequent renal tumour in children. Multi-modal treatment includes chemotherapy and surgery, with or without radiotherapy. The survival is excellent, with rates exceeding 90%. A review is presented on our experience over the last 15 years of treating Wilms' tumour in Hospital Niño Jesús, Madrid.

Patients and methods: A retrospective study was conducted on 40 consecutive paediatric patients diagnosed with nephroblastoma between 2002 and 2016 in the Hospital Niño Jesús in Madrid. The clinical characteristics, diagnostic methods, treatment, and follow-up were analysed.

Results: Of the 40 patients, 23 were boys, with a median age at diagnosis of 2.5 years (range, 4 months–15 years). Three patients underwent initial nephrectomy, three received a fine needle aspiration biopsy, followed by chemotherapy, and 34 patients started pre-operative chemotherapy directly. The median follow-up of the patients was 6.75 years (range, 10 months–13.92 years).

Two patients died from disease progression. There were no treatment-related deaths. Overall survival and event-free survival at 5 years was $94.6 \pm 3.7\%$ and $89.4 \pm 5\%$, respectively.

Conclusion: Wilms' tumour treatment is a success of modern medicine, currently achieving a survival rate of 95% in our series.

© 2017 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Illade L, Hernandez-Marques C, Cormenzana M, Lassaletta A, Andión Catalán M, Ruano D, et al. Tumor de Wilms: revisión de nuestra experiencia en los últimos 15 años. An Pediatr (Barc). 2018;88:140–149.

* Corresponding Author.

E-mail address: alassaletta.hnjs@salud.madrid.org (A. Lassaletta).

PALABRAS CLAVE

Tumor renal;
Wilms;
Nefroblastoma;
Niños

Tumor de Wilms: revisión de nuestra experiencia en los últimos 15 años**Resumen**

Introducción: El tumor de Wilms es el tumor renal más frecuente en la edad pediátrica. Su tratamiento es multimodal: incluye quimioterapia y cirugía, con o sin radioterapia. La supervivencia de estos pacientes es excelente, superando el 90%. Presentamos la experiencia de nuestro centro en el tratamiento del tumor de Wilms durante los últimos 15 años.

Pacientes y métodos: Se ha realizado un estudio retrospectivo de 40 pacientes pediátricos diagnosticados de forma consecutiva de nefroblastoma entre 2002 y 2016 en el Servicio de Hemato-Oncología pediátrica del Hospital Niño Jesús de Madrid. Se analizaron las características clínicas, los métodos diagnósticos, el tratamiento realizado y la evolución posterior.

Resultados: De los 40 pacientes, 23 eran niños con una mediana de edad al diagnóstico de 2,5 años (rango, 4 meses-15 años). A 3 pacientes se les realizó nefrectomía inicial, 3 recibieron una punción aspiración con agua fina, seguida de quimioterapia y 34 pacientes recibieron quimioterapia preoperatoria directamente. La mediana de seguimiento de los pacientes fue de 6,75 años (rango, 10 meses-13,92 años).

Dos pacientes fallecieron de progresión de su enfermedad. Ningún paciente falleció de toxicidad en relación con el tratamiento. La supervivencia global y la supervivencia libre de evento a los 5 años fue del $94,6 \pm 3,7\%$ y $89,4 \pm 5\%$, respectivamente.

Conclusión: El tratamiento del tumor de Wilms es un éxito de la medicina moderna, consiguiendo en la actualidad una supervivencia que en nuestra serie alcanza el 95%.

© 2017 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Wilms tumour or nephroblastoma is the second most common intra-abdominal cancer and the fifth most common malignancy in the paediatric age group. It accounts for approximately 6% of all paediatric cancers and is the most frequent tumour of the kidney (more than 95% of all tumours of the kidney in the paediatric age group).¹⁻³ The differential diagnosis of Wilms tumour includes neuroblastoma and other paediatric renal malignancies, such as clear cell sarcoma, malignant rhabdoid tumour and renal cell carcinoma, which have less favourable outcomes.^{1,4}

Patients with several congenital anomalies, such as WAGR syndrome, Denys-Drash syndrome, Beckwith-Wiedemann syndrome, or isolated hemihypertrophy are at higher risk of developing Wilms tumour.³

The incidence of nephroblastoma peaks between ages 2 and 5 years, and 95% of cases are diagnosed before age 10 years.⁵ The most frequent initial sign is the chance detection of an abdominal mass, followed by haematuria. Some patients may have arterial hypertension due to renal ischaemia, which is caused by the pressure exerted by the tumour on the renal artery. On occasion, patients present with systemic symptoms such as asthenia, anorexia, weight loss and fever.³ Between 10% and 25% may have disseminated disease, usually in the lungs.⁶

The management of renal tumours has advanced spectacularly since the introduction of multimodal treatment, which includes chemotherapy and surgery with or without radiation. The 5-year survival has increased drastically in the past three decades, from 25% in the pre-chemotherapy era of the late 1960s and early 1970s to 90% in the 1990s.^{3,4,7}

Two large collaborative groups have been formed for the investigation of Wilms tumour: the National Wilms Tumor Study Group (NWTSG) in the United States and the International Society for Paediatric Oncology (SIOP) in Europe. These groups disagree on the timing of surgery. The NWTSG recommends upfront nephrectomy for the purpose of histological diagnosis and accurate staging.⁸⁻¹² The SIOP Renal Tumour Study Group recommends preoperative chemotherapy to shrink the tumour and facilitate surgery—through the prevention of tumour rupture—followed by staging.^{1,3,8} The overall survival rate is similar for both approaches.^{11,13,14} Performance of a confirmatory biopsy before chemotherapy in cases of Wilms tumour with typical clinical and radiological characteristics is not routine practice in the SIOP protocols, as evidence from research comparing needle biopsy specimens collected before preoperative chemotherapy and surgical specimens from the subsequent nephrectomy in the same patients found a 95% agreement in the results.¹³

Given the high survival rate, the main goal at present is to individualise treatment based on the correct risk stratification of patients in order to achieve the highest possible cure rate while minimising the frequency and intensity of acute and late toxicity.⁵

Based on the correlation between histological characteristics and survival, the SIOP has defined 3 prognostic groups: low risk, intermediate risk and high risk.^{5,15} The most powerful predictor of an unfavourable outcome is anaplastic histology. Other histological subtypes included in the high-risk group are blastemal histology, clear cell sarcoma and renal rhabdoid tumour.^{10,13} The second most important prognostic factor is the stage. As is the case in most tumours, the lower the stage the better the prognosis.

Table 1 SIOP staging criteria for renal tumours of childhood (2001).

Stage I	The tumour is limited to the kidney There is no residual tumour in the resection margins The vessels of the renal sinus are not involved Intrarenal vessel involvement, potential involvement of capsule, adjacent tissues, renal sinus vessels and vena cava
Stage II	The tumour extends outside the renal parenchyma and may have infiltrated the capsule, adjacent tissues, renal sinus vessels or vena cava, but it is completely excised
Stage III	Incomplete excision: – Involvement of abdominal lymph nodes – Tumour rupture before or during surgery – The tumour has penetrated the peritoneal surface – Tumour thrombi present at resection margins Haematogenous metastases (lung, liver, bone, ...)
Stage IV	Lymph node metastases outside the abdominopelvic region
Stage V	Bilateral renal tumours (each side should be substaged separately)

Other factors used in the risk stratification of Wilms tumour are patient age, tumour size and response to treatment.¹⁶ Based on these factors, patients are classified into one of the 3 risk groups and treated accordingly.^{2,7}

The survival of patients with Wilms tumour is generally excellent, exceeding 90%.² The rate is 95% for patients with stages I and II Wilms tumour, 75–80% for patients with stage III, and 65–75% for patients with stage IV (Table 1). Only 15% of patients with a favourable histology experience recurrence, compared to an incidence of 50% in those with anaplastic histology. Even patients with recurrent disease have a high survival rate of 60%.⁷ The most common sites of recurrence are the lungs, pleura, tumour bed and liver. Among patients with metastases, those with liver involvement have a poorer prognosis compared to those with lung metastases.⁵

Materials and methods

During the 15-year study period (January 1, 2002 to June 1, 2016), 40 patients received a diagnosis of nephroblastoma and were managed in the Department of Paediatric Haematology and Oncology of the Hospital Infantil Universitario Niño Jesús. We also included another 2 patients who were referred to our hospital when their cancer relapsed in the analysis of relapsed patients.

We reviewed the health records of the patients to collect data on age, sex, presentation at diagnosis, histology,

Table 2 Revised SIOP classification of renal tumours of childhood (2001).

<i>Low risk tumours</i>
Cystic partially differentiated nephroblastoma
Completely necrotic nephroblastoma
<i>Intermediate risk tumours</i>
Nephroblastoma-epithelial type
Nephroblastoma-stromal type
Nephroblastoma-mixed type
Nephroblastoma-regressive type
Nephroblastoma-focal anaplasia
<i>High risk tumours</i>
Nephroblastoma-blastemal type
Nephroblastoma-diffuse anaplasia
Clear cell sarcoma of the kidney
Rhabdoid tumour of the kidney

staging, overall survival and event-free survival. We also analysed the initial treatment, type of recurrence and treatment of recurrence.

The evaluation included a complete blood count, measurement of serum creatinine and electrolyte and liver panels. These tests were performed prior to and during chemotherapy. The evaluation was completed with an abdominal ultrasound and a lung X-ray or CT scan. An abdominal MRI or CT scan was performed in most patients to assess tumour size, staging and operability.

Tumours were classified based on histology and staged according to the SIOP criteria in all patients (Tables 1 and 2).

All patients received treatment conforming to the SIOP 2001 nephroblastoma protocol. Thus, patients received preoperative chemotherapy followed by surgery, except 3 patients in whom nephrectomy was performed immediately after diagnosis. A core needle biopsy was performed in 3 patients before initiating treatment (as excisional biopsy is recommended against due to the risk of upstaging) on account of atypical clinical or radiological findings. In all 3 cases, nephroblastoma was confirmed by histological examination of the surgical specimen.

Patients with localised disease received standard chemotherapy with 4 weeks of actinomycin D and vincristine. Patients with advanced disease received 6 weeks of 3-drug chemotherapy with actinomycin D, vincristine and doxorubicin. After completing initial treatment, patients underwent a CT or MRI scan to assess the response of the tumour and plan the surgery. Tumour response was evaluated based on the reduction in the maximum diameter of the tumour from observed in the post-chemotherapy scan compared to the pre-chemotherapy scan.

When it came to postoperative treatment, 3 patients with low-risk stage I disease required no further treatment. The rest received postoperative chemotherapy for 4–34 weeks. The chemotherapy regimen was based on tumour staging and histology.

Patients with tumours limited to the kidney with favourable histology received actinomycin D and vincristine for 4 weeks. Patients with more advanced disease received actinomycin D and vincristine with or without doxorubicin for 27 weeks. Patients with unfavourable histology received

dose-intensive chemotherapy with etoposide, carboplatin, cyclophosphamide and doxorubicin, administered for 34 weeks.

Results

Tables 3 and 4 present the characteristics of our patients. Their age ranged between 4 months and 15 years, with a median of 2.5 years. Twenty-three patients (57.5%) were male. The most frequent presentation was the presence of an abdominal mass (21 patients), followed by abdominal pain and chance finding (6 patients each), haematuria and fever (3 patients each) and lastly, in a patient with a syndrome associated with a high risk of cancer—WAGR syndrome—the tumour was found during an early cancer screen (1 patient).

In our series, 4 patients had congenital anomalies: 2 had WAGR syndrome, 1 isolated hemihypertrophy and 1 ataxia-telangiectasia. Three of them responded well to treatment and are currently in first complete remission. The patient with ataxia-telangiectasia had both local and metastatic recurrence (lung and liver) refractory to chemotherapy, and died 2 months after relapsing. The poor outcome in this patient may have been associated to the need to reduce the chemotherapy dose by 25% and the contraindication of radiation therapy due to the underlying disease.

Only 3 patients required a biopsy due to their atypical clinical and radiological presentation: one aged less than 1 year at onset (11 months) and the other 2 presented with symptoms of urinary tract infection. None of the patients experienced complications from the biopsy.

Preoperative chemotherapy was given to 37 patients, who tolerated it well, and achieved a mean reduction in tumour volume of 250 mL. Only 1 patient experienced toxicity (febrile neutropaenia) from chemotherapy.

In all patients, treatment of the primary tumour consisted in radical nephrectomy. In 3 patients, the operation was performed upfront, without prior chemotherapy. In a patient with bilateral Wilms tumour, the most affected kidney was completely removed, followed by partial resection of the second kidney at a later time. Another patient was originally classified as having a stage IV tumour with nephrogenic rests in the contralateral kidney, and later received a bilateral Wilms tumour diagnosis after surgery, where he underwent radical nephrectomy of one kidney with collection of a sample for biopsy from the contralateral kidney (patient no 10). This patient was treated as if he had a stage IV tumour, with 3-drug chemotherapy and radiation therapy in the affected flank and contralateral kidney.

The distribution by stages was the following: stage I, 18 patients (45%); stage II, 9 patients (22.5%); stage III, 9 patients (22.5%); stage IV, 2 patients (5%), and stage V, 2 patients (5%).

When it came to histology, based on the revised SIOP classification of renal tumours of childhood (2001), the most frequent histological subtypes corresponded to the intermediate risk group (11 mixed, 9 regressive, 7 stromal and 1 epithelial), with only 3 patients in the low-risk group (1 cystic, 2 necrotic) and 9 patients in the high-risk group (7 blastemal type, 1 diffuse anaplasia and 1 clear cell sarcoma).

Only 10 patients received radiation therapy: 8 exclusively to the flank of the affected kidney, one to the affected flank and the contralateral kidney, and 1 to the entire abdomen (on account of peritoneal dissemination). None of the patients received lung radiation therapy as first-line treatment.

The median duration of followup was 6.75 years (range, 10 months–13.92 years). Two patients died due to disease progression. None died from chemotherapy toxicity or complications of surgery. The overall 5-year survival was $94.6 \pm 3.7\%$ and the 5-year event-free survival was $89.4 \pm 5\%$ (Fig. 1).

Fifteen percent of patients (6 out of 40) had disseminated disease at the time of diagnosis: 5 had pulmonary metastases and 1 had metastases in the lung, pleura and peritoneum. Two patients had recurrences (local and metastatic) and responded well to salvage therapy, remaining in second complete remission at the time of the last followup.

When it came to recurrence (Table 4), there were 6 patients in our series who had relapses; 4 of them were managed in our hospital from the time of diagnosis, while the other 2 were referred to the hospital when the tumour recurred. The median time elapsed between diagnosis and recurrence was 14 months (range, 7–17 months). Patients with recurrence were treated with chemotherapy, surgery, radiation therapy and autologous haematopoietic stem cell transplantation. Two patients died due to disease progression: one after the third recurrence and the other after the first recurrence, 28 and 11 months after the initial diagnosis, respectively. The first patient had blastemal histology since the initial diagnosis and suffered from ataxia-telangiectasia, which precluded the administration of the full treatment that corresponded to her risk group (as we noted above). The second patient had regressive histology at diagnosis and developed blastemal histology in the first recurrence. The other 4 patients remained alive at the time of the study, with a median duration of followup since the recurrence of 45 months (range, 26–60 months). Thus, in our case series, 66% of patients that had a recurrence remain in second complete remission.

Discussion

In this article, we analyse our experience of the past 15 years in the management of Wilms tumour. The prognosis of nephroblastoma is very good, and the greatest challenge we face at present is to achieve a cure with minimum toxicity while preserving adequate renal function.^{6,17–19} In Europe, treatment consists of preoperative chemotherapy, followed by surgical excision with or without postoperative chemotherapy/radiation therapy depending on the stage and histology of the disease.^{6,20}

Wilms tumour is diagnosed based on clinical and radiological features, and histological examination is usually not required to initiate treatment. In our series, only 3 patients required a biopsy before starting treatment, which confirmed the diagnosis of Wilms tumour in all.^{11,12}

Preoperative chemotherapy usually achieves a reduction in tumour size that facilitates surgery without major toxicity. In our study, we found that preoperative treatment achieved a reduction in tumour size of 250 mL in 90% of

Table 3 Characteristics of patients at the time of diagnosis.

PT	Age	Presentation	Biopsy	Anomalies	Post- CHEMO stage	Metastases	Post-CHEMO histology	Preoperative CHEMO	Surgery	Postoperative CHEMO
1. M	5 years	Abdominal mass	Yes	No	I	No	Regressive	Yes	Nephrectomy	-
2. F	2 years	Abdominal mass	No	WAGR	I	No	Stromal	Yes	Nephrectomy	AV1
3. M	2 years	Abdominal pain	No	No	I	No	Blastemal	Yes	Nephrectomy	AVD
4. M	3 years	Abdominal pain + fever	No	No	II	No	Stromal	Yes	Nephrectomy	AV-2
5. M	2 years	Abdominal pain + fever	No	No	I	No	Mixed	Yes	Nephrectomy	AV1
6. M	1 year	Abdominal mass	No	No	I	No	Stromal	Yes	Nephrectomy	AV1
7. F	1 year	Abdominal mass + fever	No	No	I	No	Stromal	Yes	Nephrectomy	AV1
8. M	15 years	Abdominal mass	No	No	I	Pulmonary, only on CT scan	Diffuse anaplasia	No	Nephrectomy	AVD
9. M	5 years	Asthenia + weight loss + Abdominal mass	Yes	No	IV	Pulmonary + pleural + peritoneal	Regressive	Yes	Nephrectomy	AVD
10. M	3 years	Chance finding	No	No	V	Pulmonary + contralateral nephrogenic rests	Mixed	Yes	Right nephrectomy + left partial resection.	AVD
11. F	4 years	Abdominal mass	No	No	II	Pulmonary only on CT scan	Mixed	Yes	Nephrectomy	AV-2
12. F	2 years	Abdominal mass + irritability	No	No	III	No	Stromal	Yes	Nephrectomy	AV-2
13. F	1 year	Screening	No	WAGR	III	No	Mixed	Yes	Nephrectomy	AV -2
14. F	3 years	Haematuria	No	No	I	No	Regressive	Yes	Nephrectomy	AV1
15. M	9 months	Fever + irritability	No	Hemihypertrophy	I	No	Regressive	Yes	Nephrectomy	AV1
16. F	2 years	Chance finding	No	Ataxia-telangiectasia	III	No	Blastemal	No	Nephrectomy	VP + CARBO + CYCLO + DOXO
17. F	3 years	Haematuria	No	No	III	No	Blastemal	Yes	Nephrectomy	VP + CARBO + CYCLO + DOXO
18. F	4 years	Chance finding	No	No	III	No	Regressive	Yes	Nephrectomy	AVD
19. F	3 years	Abdominal mass	No	No	III	No	Stromal	Yes	Nephrectomy	AVD
20. M	5 years	Abdominal mass	No	No	III	No	Regressive	Yes	Nephrectomy	AV-2
21. F	3 years	Abdominal mass	No	No	II	No	Mixed	Yes	Nephrectomy	AVD
22. F	1 year	Abdominal mass	No	No	II	No	Clear cell sarcoma	Yes	Nephrectomy	VP + CARBO + CYCLO + DOXO
23. M	4 years	Abdominal mass	No	No	I	No	Blastemal	Yes	Nephrectomy	AVD

Tabla 3 (Continuación)

PT	Age	Presentation	Biopsy	Anomalies	Post-CHEMO stage	Metastases	Post-CHEMO histology	Preoperative CHEMO	Surgery	Postoperative CHEMO
24. F	6 years	Fever	No	No	I	No	Mixed	Yes	Nephrectomy	AV1
25. M	9 months	Abdominal mass	No	No	I	No	Epithelial	Yes	Nephrectomy	AV1
26. F	15 years	Fever	No	No	II	No	Blastemal with diffuse anaplasia	No	Nephrectomy	AVD
27. M	4 months	Haematuria	No	No	I	No	Mixed	Yes	Nephrectomy	AV1
28. F	7 years	Abdominal mass	No	No	I	No	Regressive	Yes	Nephrectomy	AV1
29. F	5 years	Abdominal pain	No	No	I	No	Regressive	Yes	Nephrectomy	AV1
30. M	7 years	Abdominal pain	No	No	III	Pulmonary	Necrotic	Yes	Nephrectomy	AV-2
31. M	11 months	Abdominal pain	Yes	No	II	No	Mixed	Yes	Nephrectomy	AV2
32. F	2 years	Abdominal mass	No	No	II	No	Mixed	Yes	Nephrectomy	AVD
33. M	3 years	Incidental	No	No	II	No	Regressive	Yes	Nephrectomy	AV1
34. M	2 years	Abdominal mass + fever	No	No	II	No	Mixed	Yes	Nephrectomy	AVD
35. M	4 years	Chance finding	No	No	IV	Pulmonary	Blastemal	Yes	Nephrectomy	VP + CARBO + CYCLO + DOXO
36. M	1 year	Abdominal mass	No	No	V	NO	Blastemal	Yes	Right nephrectomy + left partial resection	VP + CARBO + CYCLO + DOXO
37. M	2 years	Chance finding	No	No	I	No	Cystic	Yes	Nephrectomy	-
38. F	1 year	Abdominal mass	No	No	III	No	Stromal	Yes	Nephrectomy	AVD
39. M	1 year	Abdominal mass	No	No	I	No	Necrotic	Yes	Nephrectomy	-
40. M	2 years	Abdominal mass	No	No	I	No	Mixed	Yes	Nephrectomy	AV1
PT	Radiotherapy		Status		Duration of followup		Relapse			
1. M	-		Alive		-		No			
2. F	No		Alive		15 months		No			
3. M	No		Alive		13 months		No			
4. M	No		Alive		10 months		No			
5. M	No		Alive		28 months		No			
6. M	No		Alive		36 months		No			

Tabla 3 (Continuación)

PT	Radiotherapy	Status	Duration of followup	Relapse
7. F	No	Alive	37 months	No
8. M	No	Alive	41 months	No
9. M	Abdominal	Alive	48 months	No
10. M	Flank + contralateral kidney	Alive	48 months	Lung
11. F	No	Alive	49 months	Thrombus in vena cava
12. F	Flank	Alive	52 months	No
13. F	Flank	Alive	64 months	No
14. F	No	Alive	67 months	No
15. M	No	Alive	76 months	No
16. F	No	Deceased	11 months	Local + metastatic (liver + lung)
17. F	Flank	Alive	81 months	No
18. F	Flank	Alive	85 months	No
19. F	Flank	Alive	87 months	No
20. M	Flank	Alive	81 months	No
21. F	No	Alive	81 months	No
22. F	Flank	Alive	89 months	No
23. M	No	Alive	97 months	No
24. F	No	Alive	101 months	No
25. M	No	Alive	106 months	No
26. F	No	Alive	112 months	No
27. M	No	Alive	112 months	No
28. F	No	Alive	120 months	No
29. F	No	Deceased	28 months	Local
30. M	No	Alive	120 months	No
31. M	No	Alive	127 months	No
32. F	No	Alive	128 months	No
33. M	No	Alive	130 months	No
34. M	No	Lost to followup	36 months	No
35. M	No	Alive	144 months	No
36. M	No	Lost to followup	46 months	No
37. M	No	Alive	148 months	No
38. F	Flank	Alive	148 months	No
39. M	No	Alive	154 months	No
40. M	No	Alive	167 months	No

AV1, chemotherapy regimen including actinomycin D + vincristine; AVD: actinomycin D + vincristine + doxorubicin; CARBO, carboplatin; CHEMO, chemotherapy; CYCLO, cyclophosphamide; DOXO, doxorubicin; F, female; M, male; PT, patient; VP: etoposide.

Table 4 Characteristics of patients with tumour recurrence.

Age Sex	Post-chemo staging	Post-chemo histology	Surgery	Post-surgical Tx	Time ^a and site of recurrence	Second-line Tx	Status	Months since relapse
3 years M	IV Lung metastases and nephrogenic rests in contralateral kidney	Mixed	Right nephrec- tomy + partial left nephrec- tomy	AVD + radiotherapy	17 months Lung	Chemo + Rt + autologous HSCT	Alive	31 months
4 years F	II Lung metastases (only on CT scan)	Mixed	Nephrectomy	AV-2	13 months Thrombus in vena cava	Surgery + chemo + Rt + autologous HSCT	Alive	26 months
2 years F	III	Blastemal	Nephrectomy	VP + CARBO + CYCLO + DOXO	9 months Local and metastatic (liver and lung)	Topotecan + ICE	Deceased	Disease progression: death at 11 months from initial diagnosis
5 years F	I	Regressive	Nephrectomy	AV1	7 months Local	Chemo + Rt + autologous HSCT	Deceased	2 subsequent recurrences: death 28 months after diagnosis
9 years F	III	Regressive	Nephrectomy	AVD + radiotherapy	15 months Abdominal	Surgery + Chemo + + Rt + autologous HSCT	Alive	60 months
4 years M	I	Epithelial	Nephrectomy	AV1	15 months Lung	Surgery + Chemo + Rt + autologous HSCT	Alive	58 months

AV1, chemotherapy regimen including actinomycin D + vincristine; AVD: actinomycin D + vincristine + doxorubicin; CARBO, carboplatin; CYCLO, cyclophosphamide; DOXO, doxorubicin; chemo, chemotherapy; F, female; HSCT, haematopoietic stem cell transplantation; ICE, ifosfamide + etoposide + carboplatin; M, male; Rt: radiation therapy; Tx, treatment; VP, etoposide.

^a Months elapsed from diagnosis to first relapse.




Figure 1 Overall survival (A) and event-free survival (B) in 40 patients with Wilms tumour treated in our hospital.

patients with little toxicity; 4 patients did not respond to this treatment.

Ongoing advances in our knowledge of the genetic and molecular basis of Wilms tumour will allow the future development of risk-adapted therapies better fitting individual patients, and to identify novel therapeutic targets with a more favourable efficacy/toxicity profile compared to standard chemotherapeutics.⁸ Some of the most important genetic changes described in the literature include the loss of heterozygosity for chromosomes 1p or 16q⁶ and the gain of chromosome 1q (which is the most frequent genetic change, found in up to 30% of patients). These changes are associated with less favourable outcomes and an increased risk of relapse and death.

Other mutations that lead to loss of function in tumour-suppressor and transcription factor genes involve the genes WT1, WT2, p53, FWT1, and FWT2, DROSHA or DICER1. Mutations that inactivate the WT1 gene or lead to loss of expression of the WT2 gene may lead to the persistence of nephrogenic rests that, for reasons yet unknown, can transform into Wilms tumour.^{8,10,13}

While there have been significant advances in patient stratification, the presence of anaplastic histology continues to be the most important adverse prognostic feature.⁸

In our series, the overall 5-year survival in patients with localised as well as disseminated disease was excellent, consistent with similar studies published to date.^{3,4,17,19,20}

Most recurrences of Wilms tumour occur within 2 years of diagnosis.²¹ The most frequent sites of recurrence are the lungs, abdomen and liver. Late recurrence (>5 years after diagnosis) is infrequent, occurring in 0.5% of patients, and has a similar prognosis to early recurrence.²² Recurrence survival is stratified based on risk factors (tumour histology and treatment received), and is reported in the literature as 34–64% (range, 15–85%),^{8,10,21,23} similar to the 66% observed in our series (4 of 6 patients). The factors that have a negative impact on survival are: greater age at diagnosis, advanced stage of disease and unfavourable histology. When it came to age at diagnosis, the 2 patients who died in our series had been 2 and 5 years old. As for advanced stage of

disease, all patients that had metastatic disease at diagnosis were in complete remission at the end of the study period. Lastly, as regards histology, of the 2 patients who died, 1 had blastemal histology (the patient with ataxia-telangiectasia) and 1 regressive histology.

Patients with Wilms tumour require life-long followup, because most of them end up having a single kidney, and there is risk of developing late effects of treatment or second tumours (with a risk of a second malignant neoplasm of 5–7% at 30 years).^{4,6,22,24–26} Renal function must be monitored in patients with Wilms tumour on account of having a sole functioning kidney, which puts them at risk of renal failure due to the potential nephrotoxicity of chemotherapy and glomerular hyperfiltration in the nephrons left after surgery.^{2,8,26} The probability of experiencing terminal renal failure within 20 years of diagnosis is of 0.6% in patients in the early stages of disease, increases in those with bilateral disease or associated genetic syndromes, and reaches up to 74% in patients with Denys-Drash syndrome.^{5,24}

To conclude, despite the considerable advances made in the diagnosis and treatment of these tumours in the past few decades and the high rate of survival, we cannot forget that patients continue to experience undesirable toxicity. In this sense, research efforts should aim towards minimising the side effects of treatment and to investigate new therapeutic targets, such as IGF-1 receptor inhibitors, antiangiogenic compounds, mTOR, JAK2 or telomerase inhibitors that could reduce the overall toxicity of treatment.¹

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, et al. Children's Oncology Group's 2013 blueprint for research: renal tumors. *Pediatr Blood Cancer*. 2013;60:994–1000.

2. Davidoff AM. Wilms Tumor. *Curr Opin Pediatr*. 2010;21:357–64.
3. Varan A. Wilms' tumor in children: an overview. *Nephron-Clin Pract*. 2008;108:83–90.
4. Levitt G. Renal tumours: long-term outcome. *Pediatr Nephrol*. 2012;27:911–6.
5. Davidoff AM. Wilms tumor. *Adv Pediatr*. 2012;59:247–67.
6. Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, Godzinski J, et al. Wilms tumour: prognostic factors, staging, therapy and late effects. *Pediatr Radiol*. 2008;38:2–17.
7. Balaguer Guill J, Fernández Navarro JM, Cañete Nieto A, Muro Velilla MAD, Hernández Martí M, Castel Sánchez V. Tumores renales en niños menores de un año. *An Pediatr*. 2006;64:433–8.
8. Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, et al. Advances in wilms tumor treatment and biology: progress through international collaboration. *J Clin Oncol*. 2015;33:2999–3007.
9. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. *J Clin Oncol*. 2006;24:2352–8.
10. Graf N, Furtwängler R. Preoperative chemotherapy and local stage III in nephroblastoma. *Transl Pediatr*. 2014;3:4–11.
11. Kembhavi SA, Qureshi S, Vora T, Chinnaswamy G, Laskar S, Ramadwar M, et al. Understanding the principles in management of Wilms' tumour: can imaging assist in patient selection? *Clin Radiol*. 2013;68:646–53.
12. Dumba M, Jawad N, McHugh K. Neuroblastoma and nephroblastoma: a radiological review. *Cancer Imaging*. 2015;15:1–14.
13. Acha T, Calvo C, Alfaro J, Galarón P. Wilms tumor: what's new? *Clin Transl Oncol*. 2005;7:81–94.
14. Acha Garcia T. Tumores renales. In: Madero L, Lassaletta A, Sevilla J, editors. *Hematología y oncología pediátricas*. 3.ª ed. Madrid: Editorial Ergon; 2016. p. 609–20.
15. Taran K, Sitkiewicz A, Kobos J. Histoclinical study of nephroblastoma in relation to current and previous SIOP classification of renal tumors in childhood. *Pol J Pathol*. 2010:234–9.
16. Dome JS, Perlman EJ, Graf N. Risk stratification for Wilms tumor: current approach and future directions. *Am Soc Clin Oncol*. 2014;21:5–23.
17. Verschuur A, van Tinteren H, Graf N, Bergeron C, Sandstedt B, de Kraker J. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. *J Clin Oncol*. 2012;30:3533–9.
18. Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open label, non-inferiority, randomised controlled trial. *Lancet*. 2015;386:1156–64.
19. Visser YT, Uys R, van Zyl A, Stefan DC. Nephroblastoma—a 25-year review of a South African unit. *J Med Life*. 2014;7:445–9.
20. Fawcner-Corbett DW, Howell L, Pizer BL, Dominici C, McDowell HP, Losty PD. Wilms' tumor—lessons and outcomes—a 25-year single center UK experience. *Pediatr Hematol Oncol*. 2014;31:400–8.
21. Furtwängler R, Nourkani N, Alkassar M, von Schweinitz D, Schenk JP, Rube C, et al. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies—a report from the GPOH-nephroblastoma study group. *Klin Padiatr*. 2011;223:113–9.
22. Malogolowkin M, Spreafico F, Dome JS, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM, et al. Incidence and outcomes of patients with late recurrence of Wilms' tumor. *Pediatr Blood Cancer*. 2013;60:1612–5.
23. Illhardt T, Ebinger M, Schwarze C, Feuchtinger T, Furtwängler R, Schlegel P, et al. Children with relapsed or refractory nephroblastoma: favorable long-term survival after high-dose chemotherapy and autologous stem cell transplantation. *Klin Pädiatr*. 2014;226:351–6.
24. Scalabre A, Bergeron C, Brioude F, Dainese L, Cropet C, Coulomb L'hermine A, et al. Is nephron sparing surgery justified in Wilms tumor with beckwith—Wiedemann syndrome or isolated hemihypertrophy? *Pediatr Blood Cancer*. 2016;63:1571–7.
25. Wong KF, Reulen RC, Winter DL, Guha J, Fidler MM, Kelly J, et al. Risk of adverse health and social outcomes up to 50 years after Wilms tumor: the British Childhood Cancer Survivor Study. *J Clin Oncol*. 2016;34:1772–9.
26. Cotton CA, Peterson S, Norkool P, Takashima J, Grigoriev Y, Green DM, et al. Early and late mortality after diagnosis of Wilms tumor. *J Clin Oncol*. 2009;27:1304–9.